Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite (folate antagonist) presented as a subcutaneous injection formulation for subcutaneous use. It is employed to treat autoimmune disorders, certain cancers, and ectopic pregnancy by modulating immune response and inhibiting cell proliferation.

GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across several disease pathways, primarily as an immunosuppressant and antineoplastic agent. - Rheumatoid arthritis: reduces disease activity and joint inflammation. - Psoriasis: diminishes skin lesions and plaque formation. - Certain leukemias and lymphomas: interferes with malignant cell replication. - Ectopic pregnancy: halts trophoblastic growth to allow medical management.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset occurring shortly after administration. - Fatigue: persistent tiredness not explained by disease activity. - Oral mucositis: painful sores or ulceration of the mouth lining. - Elevated liver enzymes: mild transaminase rise detectable on labs. - Low blood counts: mild reductions in white cells or platelets. - Alopecia: temporary thinning or loss of scalp hair.

Serious or Rare Side Effects: - Bone marrow suppression: severe pancytopenia requiring medical intervention. - Hepatotoxicity: significant liver injury or fibrosis. - Pulmonary fibrosis: progressive lung scarring leading to respiratory compromise. - Severe infection: opportunistic infections due to immunosuppression. - Renal failure: acute kidney injury from drug accumulation. - Anaphylaxis: rare hypersensitivity reaction with systemic symptoms.

Methotrexate requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X); teratogenic risk mandates effective contraception. - Liver disease: avoid or use with caution; regular liver function testing is essential. - Renal impairment: dose adjustment may be needed; monitor creatinine clearance. - Immunosuppression: increase vigilance for infections and avoid live vaccines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes, influencing efficacy and toxicity.

Major Interactions (Avoid): - NSAIDs: increase methotrexate plasma levels and risk of toxicity. - Penicillins: may potentiate hematologic suppression. - Sulfonamides: compete for renal tubular secretion, raising methotrexate concentrations. - Live vaccines: heightened risk of severe infection. - Proton pump inhibitors: can reduce renal clearance, elevating exposure.

Moderate Interactions (Monitor Closely): - Azathioprine or leflunomide: additive immunosuppression. - Warfarin: enhanced anticoagulant effect, monitor INR. - Oral contraceptives: reduced efficacy, consider alternative contraception. - Allopurinol: may increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: potential for additive bone‑marrow effects.